By contrast, the BRCA1/2 variants of unknown significance (VUS) demonstrated a 43% (13/30 callable) biallelic inactivation rate, with 13 homozygous variants versus five heterozygous and 12 not in tumor; the zygosity of four VUS could not be determined, including one patient (AZ-19-4313) with two somatic VUS in the same tumor (Supplemental Table 1). The gene discussed is BRCA1; the disease is neoplasm.